International Stem Cell Corporation announced that scientists in its wholly-owned subsidiary, Lifeline Cell Technology (LCT), have developed a technology to modify human stem cells by using engineered proteins, called “transducible transcription factors” or “TTFs.” TTFs are designed to pass into stem cells and direct the stem cells to change into specific cell types that can be both therapeutically-useful and can be used as revenue-generating research products.
In contrast to more traditional cell therapy methods this technology does not require the use of viruses or chemicals, and has the potential to produce safe therapeutic cells from stem cells. In addition, the
Image via Wikipedia
The University of Minnesota is proceeding with embryonic stem cell research, despite an anti-abortion group’s claim that it is illegal under a new ban on the use of state tax dollars for human cloning.
Minnesota Citizens Concerned for Life called on the university Tuesday to “cease its pursuit of human cloning and to end its violation of state law through its ongoing destruction of human embryos.” The organization cited the new cloning ban, along with legislative testimony from a U executive that the ban would stifle “ongoing” research if passed.
University spokeswoman Mary Koppel said the executive’s comments referred
Stem cells – unspecialized cells that have the potential to develop into different types of cells – play an important role in medical research. In the embryotic stage of an organism’s growth, stem cells develop into specialized heart, lung, and skin cells, among others; in adults, they can act as repairmen, replacing cells that have been damaged by injury, disease, or simply by age.
Given their enormous potential in future treatments against disease, the study and growth of stem cells in the lab is widespread and critical. But growing the cells in culture offers numerous challenges, including the constant need
International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.
These products represent milestone
Image via Wikipedia
Dr. Robert Johnson, MD, of Neurosurgical Associates of San Antonio, is presenting at the 5th Annual Stem Cell Summit in New York on February 16, 2010. Dr. Johnson will be presenting his most recent data proving the efficacy of point of care adult stem cell therapies in spine surgery. Point of care technology utilizes the patient’s own cells derived from bone marrow to inhibit bone growth in spinal fusion procedures. Dr. Johnson believes promoting cell therapy utilizing the patient’s own cells will change the future landscape of medicine.
“The use of autologous stem cells is revolutionizing